{"id":"tislelizumab-and-nintedanib","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (e.g., pneumonitis, hepatitis)"}]},"_chembl":{"chemblId":"CHEMBL4297840","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tislelizumab is a humanized anti-PD-1 monoclonal antibody that restores T-cell-mediated immune responses against cancer cells. Nintedanib is a small-molecule tyrosine kinase inhibitor targeting VEGFR, FGFR, and PDGFR, which suppresses tumor angiogenesis and fibroblast-mediated stromal remodeling. The combination aims to synergize immunotherapy with anti-angiogenic and anti-fibrotic effects.","oneSentence":"Tislelizumab blocks PD-1 to enhance anti-tumor immunity, while nintedanib inhibits multiple receptor tyrosine kinases to reduce angiogenesis and fibrosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:55.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC) with specific molecular or histological subtypes"}]},"trialDetails":[{"nctId":"NCT07485920","phase":"PHASE4","title":"A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2026-05-01","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tislelizumab and nintedanib","genericName":"Tislelizumab and nintedanib","companyName":"The Affiliated Hospital of Qingdao University","companyId":"the-affiliated-hospital-of-qingdao-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab blocks PD-1 to enhance anti-tumor immunity, while nintedanib inhibits multiple receptor tyrosine kinases to reduce angiogenesis and fibrosis. Used for Non-small cell lung cancer (NSCLC) with specific molecular or histological subtypes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}